Treatment of diabetic mice with SMSO and glibenclamide significantly reduced levels of ALT, AST, creatinine, and urea, suggesting SMSO could alleviate the liver and renal injury in diabetes mice. The gene discussed is GPT; the disease is diabetes mellitus.